ZIMMER BIOMET HOLDINGS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ZIMMER BIOMET HOLDINGS, INC. (ZBH) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $199.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $199.60M, a 30.12% increase year-over-year.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $238.30M, a 30.50% increase year-over-year.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $137.90M, a 42.57% decline year-over-year.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $231.20M, a 7.22% decline year-over-year.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was $705.10M, a 22.11% decline from fiscal 2024.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $905.20M, a 11.70% decline from fiscal 2023.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $1.03B, a 252.03% increase from fiscal 2022.
- ZIMMER BIOMET HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $291.20M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $199.60M 10-Q · filed 2026-08-05 | $437.90M 10-Q · filed 2026-08-05 | $575.80M derived: sum of 3 quarters · filed 2026-08-05 | $807.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $238.30M 10-Q · filed 2026-05-01 | $376.20M derived: sum of 2 quarters · filed 2026-05-01 | $607.40M derived: sum of 3 quarters · filed 2026-05-01 | $760.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $137.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $369.10M derived: sum of 2 quarters · filed 2026-02-20 | $522.50M derived: sum of 3 quarters · filed 2026-08-05 | $705.10M 10-K · filed 2026-02-20 |
| 2025-09-30 | $231.20M 10-Q · filed 2025-11-05 | $384.60M derived: sum of 2 quarters · filed 2026-08-05 | $567.20M 10-Q · filed 2025-11-05 | $807.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $153.40M 10-Q · filed 2026-08-05 | $336.00M 10-Q · filed 2026-08-05 | $576.10M derived: sum of 3 quarters · filed 2026-08-05 | $825.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $182.60M 10-Q · filed 2026-05-01 | $422.70M derived: sum of 2 quarters · filed 2026-05-01 | $671.90M derived: sum of 3 quarters · filed 2026-05-01 | $915.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $240.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $489.30M derived: sum of 2 quarters · filed 2026-02-20 | $732.40M derived: sum of 3 quarters · filed 2026-02-20 | $905.20M 10-K · filed 2026-02-20 |
| 2024-09-30 | $249.20M 10-Q · filed 2025-11-05 | $492.30M derived: sum of 2 quarters · filed 2025-11-05 | $665.10M 10-Q · filed 2025-11-05 | $1.08B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $243.10M 10-Q · filed 2025-08-07 | $415.90M 10-Q · filed 2025-08-07 | $835.60M derived: sum of 3 quarters · filed 2026-02-20 | $998.40M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $172.80M 10-Q · filed 2025-05-05 | $592.50M derived: sum of 2 quarters · filed 2026-02-20 | $755.30M derived: sum of 3 quarters · filed 2026-02-20 | $965.20M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $419.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $582.50M derived: sum of 2 quarters · filed 2026-02-20 | $792.40M derived: sum of 3 quarters · filed 2026-02-20 | $1.03B 10-K · filed 2026-02-20 |
| 2023-09-30 | $162.80M 10-Q · filed 2024-10-30 | $372.70M derived: sum of 2 quarters · filed 2024-10-30 | $605.40M 10-Q · filed 2024-10-30 | $475.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $209.90M 10-Q · filed 2024-08-07 | $442.60M 10-Q · filed 2024-08-07 | $312.50M derived: sum of 3 quarters · filed 2025-02-25 | $506.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $232.80M 10-Q · filed 2023-05-02 | $102.60M derived: sum of 2 quarters · filed 2025-02-25 | $296.80M derived: sum of 3 quarters · filed 2025-02-25 | $450.80M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$130.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $64.00M derived: sum of 2 quarters · filed 2025-02-25 | $218.00M derived: sum of 3 quarters · filed 2025-02-25 | $291.20M 10-K · filed 2025-02-25 |
| 2022-09-30 | $194.20M 10-Q · filed 2023-11-07 | $348.20M derived: sum of 2 quarters · filed 2023-11-07 | $421.40M 10-Q · filed 2023-11-07 | $366.70M derived: sum of 4 quarters · filed 2024-08-07 |
| 2022-06-30 | $154.00M 10-Q · filed 2023-08-01 | $227.20M 10-Q · filed 2023-08-01 | $172.50M derived: sum of 3 quarters · filed 2024-08-07 | $334.90M derived: sum of 4 quarters · filed 2024-08-07 |
| 2022-03-31 | $73.20M 10-Q · filed 2023-05-02 | $18.50M derived: sum of 2 quarters · filed 2024-08-07 | $180.90M derived: sum of 3 quarters · filed 2024-08-07 | $325.70M derived: sum of 4 quarters · filed 2024-08-07 |
| 2021-12-31 | -$54.70M derived: 8-K 12 month − 10-Q 9 month · filed 2024-08-07 | $107.70M derived: sum of 2 quarters · filed 2024-08-07 | $252.50M derived: sum of 3 quarters · filed 2024-08-07 | $445.50M 8-K · filed 2024-08-07 |
| 2021-09-30 | $162.40M 10-Q · filed 2022-11-02 | $307.20M derived: sum of 2 quarters · filed 2022-11-02 | $500.20M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $144.80M 10-Q · filed 2022-08-02 | $337.80M 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | $193.00M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$9.20M 10-K · filed 2023-02-24 | |||
| 2019-12-31 | $1.12B 8-K · filed 2022-06-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |